IP Library › Granted Patent US 7,501,452
Granted Patent B2
US 7,501,452 · App. 11/605,983 · Granted Mar 10, 2009

Treatment of xerostomia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,501,452
App. No.
11/605,983
Granted
Mar 10, 2009
Kind
B2
Abstract

Xerostomia is treated with a sulfur-containing antioxidant, such as N-acetylcysteine. Delivery compositions including polyoxyalkylene block copolymers may be used, which may be formulated to exhibit reverse-thermal viscosity behavior.

Claims (24)

1. A method for treating a patient for xerostomia, the method comprising:

administering to the patient a therapeutically effective amount of an active agent for treating xerostomia, wherein the active agent is a sulfur-containing antioxidant effective for treating for xerostomia.

2. The method of claim 1 , wherein the sulfur-containing antioxidant is N-acetylcysteine.

3. The method of claim 1 , wherein during the administering, the sulfur-containing antioxidant is in a delivery composition that is administered to the patient, the delivery composition comprising a liquid vehicle and a polyoxyalkylene block copolymer.

4. The method of claim 3 , wherein the delivery composition is in the form of a flowable fluid medium when the delivery composition is administered to the patient during the administering.

5. The method of claim 3 , wherein the sulfur-containing antioxidant is dissolved in the liquid vehicle when the delivery composition is administered to the patient during the administering.

6. The method of claim 3 , wherein the polyoxyalkylene block copolymer is dissolved in the liquid vehicle when the delivery composition is administered to the patient during the administering.

7. The method of claim 3 , wherein the liquid vehicle is water.

8. The method of claim 3 , wherein the polyoxyalkylene block copolymer is a polyoxyethylene-polyoxypropylene block copolymer.

9. The method of claim 8 , wherein polyoxyethylene comprises at least 50 weight percent of the polyoxyethylene-polyoxypropylene block copolymer.

10. The method of claim 8 , wherein the polyoxyalkylene block copolymer is a reverse-thermal gelation polymer, and the delivery composition exhibits reverse-thermal viscosity behavior over some temperatures in a range of from 1° C. to 37° C.

11. The method of claim 10 , wherein the delivery composition has a reverse-thermal gelation property and a reverse-thermal gel transition temperature in a range of from 1° C. to 37° C.

12. The method of claim 8 , wherein the polyoxyalkylene block copolymer is a poloxamer 407.

13. The method of claim 3 , wherein the sulfur-containing antioxidant comprises from 0.001 weight percent to 25 weight percent of the delivery composition.

14. The method of claim 3 , wherein the sulfur-containing antioxidant comprises from 5 weight percent to 15 weight percent of the delivery composition.

15. The method of claim 3 , wherein the polyoxyalkylene block copolymer comprises from 1 weight percent to 30 weight percent of the delivery composition.

16. The method of claim 3 , wherein the polyoxyalkylene block copolymer comprises from 7 weight percent to 18 weight percent of the delivery composition.

17. The method of claim 3 , wherein the liquid vehicle comprises from 50 weight percent to 90 weight percent of the delivery composition.

18. The method of claim 16 , wherein the liquid vehicle comprises from 60 weight percent to 85 weight percent of the delivery composition.

19. The method of claim 3 , wherein the delivery composition is in the form of an oral rinse solution when administered the delivery composition is administered to the patient during the administering, and the administering comprises introducing the oral rinse solution into the oral cavity of the patient.

20. The method of claim 1 , wherein the sulfur-containing antioxidant is at a temperature in a range of 1° C. to 10° C. when administered to the patient during the administering.

21. The method of claim 1 , wherein the administering comprises introducing the sulfur-containing antioxidant into the oral cavity of the patient for oral mucosal delivery of the sulfur-containing antioxidant.

22. The method of claim 1 , wherein the administering comprises subcutaneous placement of the sulfur-containing antioxidant in the vicinity of at least one salivary gland of the patient.

23. The method of claim 1 , wherein the administering comprises injection of the sulfur-containing antioxidant directly into at least one salivary gland of the patient.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0542 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Apr 6, 2021
From: BIOSPECIFICS TECHNOLOGIES LLC; PAR PHARMACEUTICAL, INC.; AUXILIUM US HOLDINGS, LLC; ASTORA WOMEN'S HEALTH, LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 055846/0246 →
SECURITY INTEREST Recorded Jun 8, 2017
From: ENDO PHARMACEUTICALS INC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042742/0922 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: ENDO PHARMACEUTICALS, INC.; ENDO PHARMACEUTICALS SOLUTIONS, INC.; ASTORA WOMEN'S HEALTH HOLDINGS, LLC
Reel/Frame 042362/0001 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032380/0198 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 25416/381 Recorded Jul 11, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 026572/0148 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ENDO PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026557/0350 →
RELEASE OF PATENT SECURITY INTEREST RECORDED AT REEL/FRAME 23390/120 Recorded Dec 3, 2010
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 025441/0305 →
SECURITY AGREEMENT Recorded Dec 1, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025416/0381 →
SECURITY AGREEMENT Recorded Oct 19, 2009
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 023390/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2007
From: TROHA, JANICE MARY; ABBAS, VICTORIA JEAN; ROSENTHAL, GARY JOSEPH; SCHAUER, WREN HENDERSON
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 018947/0108 →